Cargando…

Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series

OBJECTIVE: To report an efficacy of gonadotropin releasing hormone (GnRH) antagonist administration after freezing of all embryos for treatment of early type ovarian hyperstimulation syndrome (OHSS). METHODS: In 10 women who developed fulminant early type OHSS after freezing of all embryos, GnRH ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dayong, Kim, Se Jeong, Hong, Yeon Hee, Kim, Seul Ki, Jee, Byung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621074/
https://www.ncbi.nlm.nih.gov/pubmed/28989921
http://dx.doi.org/10.5468/ogs.2017.60.5.449
_version_ 1783267680531251200
author Lee, Dayong
Kim, Se Jeong
Hong, Yeon Hee
Kim, Seul Ki
Jee, Byung Chul
author_facet Lee, Dayong
Kim, Se Jeong
Hong, Yeon Hee
Kim, Seul Ki
Jee, Byung Chul
author_sort Lee, Dayong
collection PubMed
description OBJECTIVE: To report an efficacy of gonadotropin releasing hormone (GnRH) antagonist administration after freezing of all embryos for treatment of early type ovarian hyperstimulation syndrome (OHSS). METHODS: In 10 women who developed fulminant early type OHSS after freezing of all embryos, GnRH antagonist (cetrorelix 0.25 mg per day) was started at the time of hospitalization and continued for 2 to 4 days. Fluid therapy and drainage of ascites was performed as usual. RESULTS: Early type OHSS was successfully treated without any complication. At hospitalization, the median (95% confidence interval [CI]) of the right and the left ovarian diameter was 10.0 cm (7.6 to 12.9 cm) and 8.5 cm (7.5 to 12.6 cm). After completion of GnRH antagonist administration, it was decreased to 7.4 cm (6.2 to 10.7 cm) (P=0.028) and 7.8 cm (5.7 to 12.2 cm) (P=0.116), respectively. The median duration of hospital stay was 6 days (3 to 11 days). Trans-abdominal drainage of ascites was performed in 2 women and drainage of ascites by percutaneous indwelling catheter was performed in 4 women. No side effect of GnRH antagonist was noted. CONCLUSION: GnRH antagonist administration appears to be safe and effective for women with fulminant early type OHSS after freezing all embryos. Optimal dose or duration of GnRH antagonist should be further determined.
format Online
Article
Text
id pubmed-5621074
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society
record_format MEDLINE/PubMed
spelling pubmed-56210742017-10-06 Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series Lee, Dayong Kim, Se Jeong Hong, Yeon Hee Kim, Seul Ki Jee, Byung Chul Obstet Gynecol Sci Original Article OBJECTIVE: To report an efficacy of gonadotropin releasing hormone (GnRH) antagonist administration after freezing of all embryos for treatment of early type ovarian hyperstimulation syndrome (OHSS). METHODS: In 10 women who developed fulminant early type OHSS after freezing of all embryos, GnRH antagonist (cetrorelix 0.25 mg per day) was started at the time of hospitalization and continued for 2 to 4 days. Fluid therapy and drainage of ascites was performed as usual. RESULTS: Early type OHSS was successfully treated without any complication. At hospitalization, the median (95% confidence interval [CI]) of the right and the left ovarian diameter was 10.0 cm (7.6 to 12.9 cm) and 8.5 cm (7.5 to 12.6 cm). After completion of GnRH antagonist administration, it was decreased to 7.4 cm (6.2 to 10.7 cm) (P=0.028) and 7.8 cm (5.7 to 12.2 cm) (P=0.116), respectively. The median duration of hospital stay was 6 days (3 to 11 days). Trans-abdominal drainage of ascites was performed in 2 women and drainage of ascites by percutaneous indwelling catheter was performed in 4 women. No side effect of GnRH antagonist was noted. CONCLUSION: GnRH antagonist administration appears to be safe and effective for women with fulminant early type OHSS after freezing all embryos. Optimal dose or duration of GnRH antagonist should be further determined. Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society 2017-09 2017-09-18 /pmc/articles/PMC5621074/ /pubmed/28989921 http://dx.doi.org/10.5468/ogs.2017.60.5.449 Text en Copyright © 2017 Korean Society of Obstetrics and Gynecology http://creativecommons.org/licenses/by-nc/3.0/ Articles published in Obstet Gynecol Sci are open-access, distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Dayong
Kim, Se Jeong
Hong, Yeon Hee
Kim, Seul Ki
Jee, Byung Chul
Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series
title Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series
title_full Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series
title_fullStr Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series
title_full_unstemmed Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series
title_short Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series
title_sort gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621074/
https://www.ncbi.nlm.nih.gov/pubmed/28989921
http://dx.doi.org/10.5468/ogs.2017.60.5.449
work_keys_str_mv AT leedayong gonadotropinreleasinghormoneantagonistadministrationfortreatmentofearlytypesevereovarianhyperstimulationsyndromeacaseseries
AT kimsejeong gonadotropinreleasinghormoneantagonistadministrationfortreatmentofearlytypesevereovarianhyperstimulationsyndromeacaseseries
AT hongyeonhee gonadotropinreleasinghormoneantagonistadministrationfortreatmentofearlytypesevereovarianhyperstimulationsyndromeacaseseries
AT kimseulki gonadotropinreleasinghormoneantagonistadministrationfortreatmentofearlytypesevereovarianhyperstimulationsyndromeacaseseries
AT jeebyungchul gonadotropinreleasinghormoneantagonistadministrationfortreatmentofearlytypesevereovarianhyperstimulationsyndromeacaseseries